Title,PMID
Lapatinib plus capecitabine in women with HER-2 positive advanced breast cancer: final survival analysis of phase III randomized trial,20736298
Lapatinib plus capecitabine for HER2-positive advanced breast cancer,17192538
Clinical Cardiac Tolerability of Trastuzumab,14722042
Bleeding risk with trastuzumab (Herceptin) treatment,10612314
Clinical cardiac tolerability of trastuzumab,14722042
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741,12668651
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial,11157009
Clinical cardiac tolerability of trastuzumab,14722042
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Clinical Cardiac Tolerability of Trastuzumab,14722042
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer,11919237
docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial,15020608
Clinical Cardiac Tolerability of Trastuzumab,14722042
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer,18323546
Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early- stage breast cancer,18323544
Paclitaxel plus Bevacizumab versus Paclitaxel alone for metastatic breast cancer,18160686
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer,11709565
Premedication strategy for weekly paclitaxel,12197222
Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer,12228205
Taxanes in elderly breast cancer patients,15145508
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741,12668651
Bisphosphonates in the adjuvant setting of breast cancer therapy- -effect on survival: a systematic review and meta-analysis,23990894
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026],16542503
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada – Clinical Trials Group,8636752
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients,10653871
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer,15014181
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004,15545664
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,14551341
Clinical Cardiac Tolerability of Trastuzumab,14722042
Trastuzumab emtansine for HER2-positive advanced breast cancer,23020162
Bleeding risk with trastuzumab (Herceptin) treatment,10612314
Clinical Cardiac Tolerability of Trastuzumab,14722042
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer,15014181
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004,15545664
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,14551341
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node- positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial,11157009
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Bleeding risk with trastuzumab (Herceptin) treatment,10612314
Clinical Cardiac Tolerability of Trastuzumab,14722042
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis,23990894
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node- positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial,11157009
Clinical Cardiac Tolerability of Trastuzumab,14722042
Bleeding risk with trastuzumab (Herceptin) treatment,10612314
Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group,18317582
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels,11863115
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects,16322118
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer,16940806
Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel,22054386
Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma,22287742
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer,21587257
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis,18512708
Clinical Cardiac Tolerability of Trastuzumab,14722042
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer,22149875
Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial),10907942
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer,15014181
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,14551341
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Adjuvant ovarian suppression in premenopausal breast cancer,25901438
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer,24881463
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial,21087898
Endocrine Therapy plus zoledronic acid in premenopausal breast cancer,19484818
Clinical Cardiac Tolerability of Trastuzumab,14722042
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group,11352951
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer,15014181
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004,15545664
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,14551341
High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology,18325057
Active surveillance for early-stage prostate cancer: review of the current literature,18306379
Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005,18353387
Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer,18581118
Mid-term results demonstrate salvage high intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer,18508188
Salvage HIFU for recurrent prostate cancer after radiotherapy,18852702
Lapatinib plus capecitabine in women with HER-2 positive advanced breast cancer: final survival analysis of phase III randomized trial,20736298
Lapatinib plus capecitabine for HER2-positive advanced breast cancer,17192538
Clinical Cardiac Tolerability of Trastuzumab,14722042
Bleeding risk with trastuzumab (Herceptin) treatment,10612314
Clinical cardiac tolerability of trastuzumab,14722042
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741,12668651
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial,11157009
Clinical cardiac tolerability of trastuzumab,14722042
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Clinical Cardiac Tolerability of Trastuzumab,14722042
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer,11919237
docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial,15020608
Clinical Cardiac Tolerability of Trastuzumab,14722042
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer,18323546
Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early- stage breast cancer,18323544
Paclitaxel plus Bevacizumab versus Paclitaxel alone for metastatic breast cancer,18160686
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer,11709565
Premedication strategy for weekly paclitaxel,12197222
Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer,12228205
Taxanes in elderly breast cancer patients,15145508
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741,12668651
Bisphosphonates in the adjuvant setting of breast cancer therapy- -effect on survival: a systematic review and meta-analysis,23990894
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026],16542503
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada – Clinical Trials Group,8636752
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients,10653871
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer,15014181
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004,15545664
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,14551341
Clinical Cardiac Tolerability of Trastuzumab,14722042
Trastuzumab emtansine for HER2-positive advanced breast cancer,23020162
Bleeding risk with trastuzumab (Herceptin) treatment,10612314
Clinical Cardiac Tolerability of Trastuzumab,14722042
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer,15014181
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004,15545664
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,14551341
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node- positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial,11157009
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Bleeding risk with trastuzumab (Herceptin) treatment,10612314
Clinical Cardiac Tolerability of Trastuzumab,14722042
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis,23990894
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node- positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial,11157009
Clinical Cardiac Tolerability of Trastuzumab,14722042
Bleeding risk with trastuzumab (Herceptin) treatment,10612314
Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group,18317582
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels,11863115
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects,16322118
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer,16940806
Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel,22054386
Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma,22287742
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer,21587257
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis,18512708
Clinical Cardiac Tolerability of Trastuzumab,14722042
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer,22149875
Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial),10907942
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer,15014181
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,14551341
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Adjuvant ovarian suppression in premenopausal breast cancer,25901438
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer,24881463
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial,21087898
Endocrine Therapy plus zoledronic acid in premenopausal breast cancer,19484818
Clinical Cardiac Tolerability of Trastuzumab,14722042
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide,19652050
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy,20232087
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group,11352951
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer,15014181
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004,15545664
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,14551341
VP-16 and Cisplatin as first-line therapy for small-cell lung cancer,2997406
Treatment of poorly differentiated neuroendocrine tumours with Etoposide and Cisplatin,10604732
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma,14716761
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports,9402181
Addition of Bevacizumab to bolus Fluorouracil and Leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial,15738537
Combined analysis of efficacy: the addition of Bevacizumab to Fluorouracil/Leucovorin improves survival for patients with metastatic colorectal cancer,15867200
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study,25744576
Capecitabine and oxaliplatin for advanced esophagogastric cancer,20200397
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial,18665167
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer,20678012
Capecitabine and oxaliplatin for advanced esophagogastric cancer,20200397
Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus,27236421
A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma,27225939
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer,9807987
Toxicities of targeted therapy and their management in kidney cancer,21277078
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities,21490127
Irinotecan combined with Fluorouracil compared with Fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial,10744089
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports,9402181
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study,14657227
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial,15738537
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial,10744089
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports,9402181
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study,14657227
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial,17227978
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study,14657227
Addition of Bevacizumab to bolus Fluorouracil and Leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial,15738537
Combined analysis of efficacy: the addition of Bevacizumab to Fluorouracil/Leucovorin improves survival for patients with metastatic colorectal cancer,15867200
Capecitabine and oxaliplatin for advanced esophagogastric cancer,20200397
Addition of Bevacizumab to bolus Fluorouracil and Leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial,15738537
Combined analysis of efficacy: the addition of Bevacizumab to Fluorouracil/Leucovorin improves survival for patients with metastatic colorectal cancer,15867200
Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy,17276620
ACT II: The second UK phase III anal cancer trial,16097568
Capecitabine and oxaliplatin for advanced esophagogastric cancer,20200397
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study,19908093
Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma,22824821
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07,17470851
Phase II Study of sorafenib in patients with advanced hepatocellular carcinoma,16908937
Everolimus for advanced pancreatic neuroendocrine tumors,21306238
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study,14657227
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience,19917862
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial,18640937
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma,14716761
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports,9402181
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104),22773551
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study,11304782
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study,11689577
Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations,20622645
Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis,20691606
Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis,20598574
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization,19552767
Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease,19346815
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients,18525307
90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience,18520231
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial,9196156
The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review,16341310
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports,9402181
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine,24131140
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07,17470851
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy,22614976
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer,18521686
Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study,19917863
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin,19103728
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial,20100962
Methods to improve efficacy of intravesical mitomycin: results of a randomized phase III trial,11309436
Chemotherapy for small cell carcinoma of prostatic origin,1311396
Extrapulmonary small-cell carcinoma: a single-institution experience,15231859
Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements,14651212
Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin,10458260
Increased survival with enzalutamide in prostate cancer after chemotherapy,22894553
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153,29442139
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors,28520840
Sorafenib in advanced clear-cell renal-cell carcinoma,17215530
Alpha emitter radium 223 and survival in metastatic prostate cancer,23863050
Toxicities of targeted therapy and their management in kidney cancer,21277078
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities,21490127
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial,23598172
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153,29442139
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points,8656243
BCG immunotherapy for transitional-cell carcinoma in situ of the bladder,8573479
BCG immunotherapy of bladder cancer: 20 years on,10335805
Megadose vitamins in bladder cancer: a double-blind clinical trial,8254816
Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration,15939530
Cisplatin and 5-fluorouracil in advanced cancer of the penis,1538445
A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer,19306412
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial,20888992
Abiraterone and increased survival in metastatic prostate cancer,21864182
Abiraterone in metastatic prostate cancer without previous chemotherapy,23228172
Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis,12801735
Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration,15939524
Combination chemotherapy in advanced adrenocortical carcinoma,22551107
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial,24637997
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer,12743129
Clinical features of hypersensitivity reactions to carboplatin,10561172
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer,12743129
Identifying patients unlikely to benefit from further chemotherapy: A descriptive study of outcome at each relapse in ovarian cancer,15894355
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer,12743129
Improved survival with bevacizumab in advanced cervical cancer,24552320
EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis,23233709
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial,24637997
Clinical response in patients with ovarian cancer treated with metronomic chemotherapy,28275392
Bevacizumab plus low- dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer,21079407
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial,24637997
CA125 response in associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup,12114425
Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer,16222310
Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report,8690289
Tamoxifen for relapse of ovarian cancer,20238312
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study,12860964
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials,15717738
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials,15717738
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy,15534360
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site,21684027
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC):a comprehensive analysis by tumour site,21684027
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous- cell carcinoma of the head and neck,15128893
Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies,11169936
Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type,11865813
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the Eastern Cooperative Oncology Group,15908667
Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers,9470832
Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma,11745288
A phase II study of carboplatin in nasopharyngeal carcinoma,9143400
Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma,8765441
Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck,1732427
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer,25671254
Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer,18407933
Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study,18404784
Nivolumab for recurrent squamous-cell carcinoma of the head and neck,27857112
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma,23288508
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153,29442139
Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck,1732427
Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study,12181249
A phase II study of carboplatin in nasopharyngeal carcinoma,9143400
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer,15341981
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck,10507770
Docetaxel: an active drug for squamous cell carcinoma of the head and neck,8622087
Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck,16467544
Platinum-based chemotherapy plus cetuximab in head and neck cancer,18784101
Cetuximab: Adverse event profile and recommendations for toxicity management,15973844
Management and preparedness for infusion and hypersensitivity reactions,17522249
Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy,9292951
Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma,9302303
The response of adenoid cystic carcinoma to tamoxifen,9509115
Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma,16091497
Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer,23640345
Unusual adverse event with vandetanib in metastatic medullary thyroid cancer,22162581
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer,20371662
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta- analysis of clinical trials,22882307
Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma,16721741
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression free survival analysis of a phase III randomized trial,11956263
Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma,9307718
Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study,17415808
A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma,10070305
Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma,10093695
Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma,12400975
Nivolumab for recurrent squamous-cell carcinoma of the head and neck,27857112
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma,23288508
Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's Sarcoma after failure of standard chemotherapy,9053490
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide,9801394
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia,11559723
Ruxolitinib versus standard therapy for the treatment of polycythemia vera,25901433
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial,11806971
High-dose melphalan with autotransplantation for refractory multiple myeloma: Results of a Southwest Oncology Group phase II trial,10561273
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma,12736280
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib,21865346
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia,16373661
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis,7700286
A clinical update in polycythemia vera and essential thrombocythemia,10967156
Anagrelide: a new drug for treating thrombocytosis,3362187
Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders,9025162
Long-term use of anagrelide in young patients with essential thrombocythemia,11159509
The paediatric cytarabine syndrome can be viewed as a drug- induced cytokine release syndrome,14871258
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation,23613521
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes,19255328
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation,23314834
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia,27081178
Efficacy of lenalidomide in myelodysplastic syndromes,15703420
Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation,20950702
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia,11287972
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome,11287973
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias,24180494
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710,20705755
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia,16373661
Management of Adverse Events Following Treatment with Anti-Programmed Death-1 Agents,27401894
VP-16 and cisplatin as first-line therapy for small-cell lung cancer,2997406
First-line crizotinib versus chemotherapy in ALK-positive lung cancer,25470694
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer,23724913
Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: An analysis of Veterans Health Administration data,25422491
Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol,16087941
Screening for epidermal growth factor receptor mutations in lung cancer,19692684
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small cell lung cancer,20681066
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial,11432888
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non–small-cell lung cancer,11870177
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer,18506025
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin- pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer,19828561
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy,10811675
Irinotecan plus cisplatin compared to etoposide plus cisplatin for extensive small-cell lung cancer,11784874
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations,23816960
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153,29442139
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors,28520840
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153,29442139
Pembrolizumab versus Chemotherapy for PD-L1-Postive Non-Small Cell Lung Cancer,27718847
Management of Adverse Events Following Treatment with Anti-Programmed Death-1 Agents,27401894
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma,12860938
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma,12177114
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin,10506594
Red wine decreases cyclosporine bioavailability,11719733
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies,22438256
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions,24401022
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia,19652068
Lenalidomide after stem-cell transplantation for multiple myeloma,22571201
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma,22571202
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma,22571202
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341,12393500
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study,17138816
Once- versus twice-weekly bortezomib induction therapy with CyCorD in newly diagnosed multiple myeloma,20413666
Prospective Comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma,18768528
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial,20823406
How I treat multiple myeloma in younger patients,19861683
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis,25202139
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses,24456586
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma,21355097
Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia,11709569
How I treat hemophagocytic lymphohistiocytosis,21828139
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis,16937360
Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH,29296904
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia,20194844
"Chronic lymphocytic leukemia in less fit patients: ""slow-go""",21774745
A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia,22405931
The clinical pharmacology of methotrexate: new applications of an old drug,342086
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07,12637469
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy,19861575
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341,12393500
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study,17138816
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma,18645194
Once- versus twice-weekly bortezomib induction therapy with CyCorD in newly diagnosed multiple myeloma,20413666
Prospective Comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma,18768528
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis,25202139
The clinical pharmacology of methotrexate: new applications of an old drug,342086
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07,12637469
Prevention of thalidomide- and lenalidomide- associated thrombosis in myeloma,18094721
Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review,9508210
Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors,16484704
Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database,17156591
Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients,19337444
Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement,17418085
SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group,22919026
Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population,27183991
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions,24401022
Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study,24638012
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients,24157580
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients,24157580
“Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma,11346336
Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study,22614995
Low-intensity therapy in adults with Burkitt’s lymphoma,24224624
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma,23574119
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy,11929754
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis,25161267
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma,7680764
Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease,17541233
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease,15998837
Siltuximab for multicentric Castleman disease,25110138
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX) : a randomised controlled trial,21131037
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study,24421329
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma,25439696
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase ½ GAUGUIN study,25143487
Phase 1 study results of the type II glycoengineered humanized anti- CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients,22431570
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies,22438256
Randomized Phase II Trial Comparing Obinutuzumab (GA101) with Rituximab in Patients with Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study,26282650
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions,24401022
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies,23045577
Treatment of fludarabine-refractory chronic lymphocytic leukemia,19402170
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia,23782158
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies,23045577
Treatment of fludarabine-refractory chronic lymphocytic leukemia,19402170
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia,23782158
Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity,15160953
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen,8622041
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study,12181251
Topical carmustine (BCNU) in the treatment of mycosis fungoides,14686972
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study,22614995
Merkel cell carcinoma: prognosis and treatment of patients from a single institution,15800320
Merkel cell carcinoma clinical practice guidelines in oncology,19777698
Efficacy and safety of vismodegib in advanced basal-cell carcinoma,22670903
Nivolumab in previously untreated melanoma without BRAF mutation,25399552
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153,29442139
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study,15169796
Nivolumab in previously untreated melanoma without BRAF mutation,25399552
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153,29442139
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors,28520840
Pembrolizumab versus ipilimumab in advanced melanoma,25891173
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial,25034862
Topical imiquimod treatment of a cutaneous melanoma metastasis,10954675
Topical imiquimod in the treatment of metastatic melanoma to skin,12622616
Treatment of stage IA cutaneous t-cell lymphoma with topical application of the immune response modifier imiquimod,12224972
Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod,17553050
Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma,21242584
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe,15888150
Successful treatment and management of large superficial basal cell carcinomas with topical imiquimod 5% cream: A case series and review,21781010
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,21639810
Management of Immune-related adverse events and kinetics of response with ipilimumab,22614989
Ipilimumab activity in advanced uveal melanoma,23211837
Managing immune-related adverse events to ipilimumab: a nurse’s guide,22459539
Management of immune-related adverse events and kinetics of response with ipilimumab,22614989
Ipilimumab plus darcarbazine for previously untreated metastatic melanoma,21639810
Ipilimumab-induced thrombocytopenia in patient with metastatic melanoma,21807763
Improved survival with Ipilimumab in patients with metastatic melanoma,20525992
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody),19242368
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy,21833591
Ipilimumab activity in advanced uveal melanoma,23211837
Managing immune-related adverse events to ipilimumab: a nurse’s guide,22459539
A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses,10459115
Topical photodynamic therapy in the treatment of actinic keratoses and Bowen’s disease in transplant recipients,14724445
Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen’s disease,8977678
5-Aminolevulinic acid-based photodynamic therapy for the treatment of two patients with extramammary Paget's disease,15906538
Temozolomide and oral vp-16 for children and young adults with recurrent or treatment-induced malignant gliomas,16047359
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma,12673724
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules,12671695
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high grade glioma,9332462
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly,11788630
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly,18477663
Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b,18187195
Mitomycin: clinical applications in ophthalmic practice,16526821
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study,10963638
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial,17046465
The pharmacological treatment of aggressive fibromatosis: a systematic review,12562642
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone,12594313
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone,12594313
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected],17602081
Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas,20520541
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients,12460784
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study,11705489
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor,11287975
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate,16862153
STI571: A paradigm of new agents for cancer therapeutics,11773186
Progression-free survival in gastrointestinal stromal tumours with high-dose Imatinib: randomised trial,15451219
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group,18955451
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors,20457867
2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology,12065567
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial,22614970
Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor,24046124
Results of multimodal treatment for desmoplastic small round cell tumors,15868593
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants,19018081
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults,3114435
Dose-intensive chemotherapy in advanced adult soft tissue sarcoma,12113242
2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology,12065567
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone,12594313
2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology,12065567
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone,12594313
Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST),17533389
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis,19793678
Anaphylactic shock following intravenous administration of lignocaine,9311409
Systemic lidocaine for neuropathic pain relief,10863041
Parenteral lidocaine for severe intractable pain in six hospice patients continued at home,15859746
Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications,15718327
Proposal for classifying the acute emetogenicity of cancer chemotherapy,8996130
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference,16314401
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy- induced nausea and vomiting and of nausea and vomiting in advanced cancer patients,27664248
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5- day cisplatin-based germ cell tumor chemotherapy,23274926
Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moserately emetogenic multiple-day chemotherapy,19135359
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer,20975064
Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use,20555090
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis,19407261
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients,16705125
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study,16087945
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes,20051958
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia,18314434
Epoetin alfa in patients with advanced-stage Hodgkin’s lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial,20368566
Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide,18467726
The diagnosis and management of anaphylaxis: An updated practice parameter,15753926
Epinephrine: the drug of choice for anaphylaxis,23724601
Adrenaline for the treatment of anaphylaxis: cochrane systematic review,19178399
Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock,18843712
Acute management of cancer-related hypercalcemia,8740333
Hypercalcemia and bone resorption in malignancy,7634618
Hypercalcemia and electrolyte disturbances in malignancy,8811300
Acetylsalicylic acid and montelukast block mast cell mediator- related symptoms during rapid desensitization,19230468
Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol,15477639
Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience,24937161
Effects of marijuana smoking on the lung,23802821
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary,27157931
Interleukin-2 and regulatory T cells in graft-versus-host disease,22129252
Stability issues of parenteral chemotherapy drugs,17621564
Low-intensity therapy in adults with Burkitt's lymphoma,24224624
Stability of fluorouracil administered through four portable infusion pumps,2816958
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial,11309436
Stability of oxaliplatin in infusion bags containing 5% dextrose injection,17823107
Stability of fluorouracil administered through four portable infusion pumps,2816958
Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy,14570094
Ifosfamide-related encephalopathy in elderly patients: report of five cases and review of the literature,17953463
Ifosfamide encephalopathy and methylene-blue: a case report,8879383
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature,10646879
Methylene blue for ifosfamide-associated encephalopathy,7700329
Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue,7510815
Local reactions to imiquimod in the treatment of basal cell carcinoma,23031368
Topical treatment of melanoma skin metastases with imiquimod: a review,25756475
Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod,12224972
Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod,17553050
Topical imiquimod treatment of a cutaneous melanoma metastasis,10954675
Topical imiquimod in the treatment of metastatic melanoma to skin,12622616
Clinical pharmacokinetics of estramustine phosphate,6375076
Pharmacokinetics and pharmacodynamics of estramustine phosphate,9515186
Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4- carboxamide (AIC) following different dose schedules,7172404
Micronucleus analysis in peripheral blood lymphocytes from melanoma patients treated with dacarbazine,9677451
Stability of dacarbazine in amber glass vials and polyvinyl chloride bags,12132562
Intrathecal dacarbazine treatment of leptomeningeal malignant melanoma,1635089
Topical bleomycin for the treatment of dysplastic oral leukoplakia,9708924
Intratumoral therapy with bleomycin for cystic craniopharyngiomas in children,11124639
A clinical review of bleomycin--a new antineoplastic agent,4122362
Bleomycin pulmonary toxicity: current status and future directions,1384147
Factors influencing postoperative morbidity and mortality in patients treated with bleomycin,77697
Risk factors of anesthesia and surgery in bleomycin-treated patients,6191044
Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats,2443992
Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours,9792151
Perioperative considerations for patients treated with bleomycin,1706974
Complications of retroperitoneal lymph node dissection,3381370
Bleomycin and subsequent anaesthesia: a retrospective study at Vancouver General Hospital,6160899
Vandetanib for the treatment of medullary thyroid carcinoma,24259657
Co-administration strategy to enhance brain accumulation of vandetanib by modulating P- glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors,22633931
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study,11986207
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath- 1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL),12130484
Pharmacokinetics of CAMPATH-1H: Assay development and validation,11792397
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration,15090452
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H,11535503
Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents,9167750
Determinants of the elimination of methotrexate and 7-hydroxy- methotrexate following high-dose infusional therapy to cancer patients,16842380
The clinical pharmacology of methotrexate: new applications of an old drug,342086
Neurologic complications of cancer chemotherapy,16769421
Carboxypeptidase-G2 rescue in a patient with high dose methotrexate- induced nephrotoxicity,19956493
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma,15139068
Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy,19076159
Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors,20393020
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels,11863115
Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma,22287742
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer,16940806
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects,16322118
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07,12637469
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors,24345751
Bosutinib for the treatment of chronic myeloid leukemia,25736937
Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients,1592361
Etiology and treatment of chemotherapeutic agent extravasation injuries: a review,3298560
Toxicity of the topoisomerase II inhibitors,15794715
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects,17577017
American society of clinical oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants,19018081
Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d’Oncologie Pédiatrique,12637473
Effectiveness of long-term cabergoline treatment for giant prolactinoma: Study of 12 men,17287412
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points,8656243
Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy,2373666
Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program,16197986
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer,9440742
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer,10675076
Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment,17921105
Severe interstitial pneumonitis associated with docetaxel administration,11857321
Therapy-induced toxicity of the lungs: an overview,19331213
Practical aspects of weekly docetaxel administration schedules,15477638
Docetaxel administration schedule: from fever to tears? a review of randomised studies,15911234
Acute hypersensitivity reactions to chemotherapy agents: an overview,20632960
Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol,21720178
Prevention and management of antineoplastic-induced hypersensitivity reactions,11676304
Management and preparedness for infusion and hypersensitivity reactions,17522249
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents,19354063
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments,15721432
Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions,10997824
Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand,15994152
Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer,19222453
High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study,15140550
Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer,17260498
Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report,21692829
Drug interactions in cancer therapy,16794637
Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy,16809732
Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy,19913890
Docetaxel administered on a weekly basis for metastatic breast cancer,10715290
Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient,16636537
Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer,16935890
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986,15861412
Superficial bladder cancer: the role of interferon-alpha,9598463
A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder,2201795
Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity,8757368
Drug interaction between alpha interferon and erythropoietin,2016633
Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b,18187195
Stability of an extemporaneously prepared recombinant human interferon alfa-2b eye drop formulation,17687060
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications,9848789
Pharmacokinetics of all-trans-retinoic acid in Japanese patients with acute promyelocytic leukemia,8713573
All-trans-retinoic acid (ATRA): pediatric acute promyelocytic leukemia,9615322
All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study,7808021
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes,10803936
Prophylaxis of symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with all-trans retinoic acid,7817703
Hypercalcemia associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia,8501972
All-trans-retinoic acid-induced scrotal ulcerations in a patient with acute promyelocytic leukemia,10906659
All-trans-retinoic acid and pseudotumor cerebri,9031073
Sweet's syndrome involoving the musculoskeletal system during treatment of promyelocytic leukemia with all-trans retinoic acid,8618455
Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management,9220656
Pseudotumour cerebri in acute promyelocytic leukemia: improvement despite continued ATRA therapy,10466446
Sweet's syndrome followed by retinoic acid syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid,10446491
Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors,7751898
Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma,20731477
Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma,20140617
Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease,21689088
Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease,26634298
Pegylated interferon alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera,18650451
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study,8040664
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial,10697032
Advanced breast cancer: a phase II trial with gemcitabine,7595731
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer,10697031
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer,10784633
A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma,10864199
Fatal liver failure after the administration of raltitrexed for cancer chemotherapy: a report of two cases,10951354
Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity,9528843
Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma,10901362
Drug Prescribing in Renal Failure,378644
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer,11896096
Clinical practice guidelines for the prevention and treatment of cancer therapy- induced oral and gastrointestinal mucositis,15108223
Neurologic complications of cancer chemotherapy,16769421
Pyridoxine for the palmar-plantar erythrodysesthesia syndrome,2529807
Pyridoxine therapy for palmar-planter erythrodysesthesia associated with continuous 5- fluorouracil infusion,2345070
Warfarin-5-FU interaction: a consecutive case series,10600095
An adverse interaction between warfarin and fluoropyrimidines revisited,16197620
Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5- fluorouracil therapy,15843293
Different intravenous administration techniques for 5-Fluorouracil pharmacokinetics and pharmacodynamic effects,8639317
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction,21609928
Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer,16012727
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction,12853359
The effects of impaired liver function on the elimination of antineoplastic agents,1554959
Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study-- FinnBladder III long-term results,15748389
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee,15994146
Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas: five-year results with epirubicin and ifosfamide,12552955
Increasing single epirubicin doses in advanced soft tissue sarcomas,11870176
Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer,15385141
Use of chemotherapy during human pregnancy,15120665
Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature,14981994
Successful chemotherapy including epirubicin in a pregnant non-Hodgkin's lymphoma patient,8750642
Eclampsia after polychemotherapy for nodal-positive breast cancer during pregnancy,8841812
Toxicity of the topoisomerase II inhibitors,15794715
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects,17577017
American society of clinical oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants,19018081
Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d’Oncologie Pédiatrique,12637473
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points,8656243
Treatment of chemotherapy extravasation: current status,6378380
Vesicant extravasation: myths and realities,7708525
The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: Preliminary evidence of a potentially common drug interaction,9543613
Drug interactions with the taxanes: clinical implications,11545542
Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions,10668172
Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer,10511918
Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients,10561171
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer,11304775
Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity,10811677
A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences,17997459
Does cisplatin (CDDP)function as a modulator of 5-fluorouracil (5-FU) antitumor action? A study based on a clinical trial,15647947
Cisplatin pharmacokinetics: applications of a physiological model,3051521
Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin,10458260
Comparative clinical pharmacology of cisplatin and carboplatin,9322881
Pharmacokinetics of Anticancer Drugs in Children,3555940
Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis,23793866
High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis,21810688
Supportive Care of Children with Cancer,10086957
Anaphylaxis to cisplatin following nine previous uncomplicated cycles,12494253
Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group,1735009
The diagnosis and management of desmoplastic small round cell tumor: a review,21577112
A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy,7577484
The management of malignant hypercalcaemia,8957154
Acute management of cancer-related hypercalcemia,8740333
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer,11575286
Bisphosphonates and avascular necrosis of the jaws,14738134
Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia,9890546
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates,18558816
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus,25414052
Intravenous pamidronate: infusion rate and safety,7873459
Safety of pamidronate in patients with renal failure and hypercalcemia,8706358
Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer,22781385
Ponatinib: a review of its use in adults with chronic myeloid leukaemia or philadelphia chromosome-positive acute lymphoblastic leukaemia,24807266
Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia,24265264
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions,24401022
Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer,25258420
Ceritinib: A primer for pharmacists,27738095
Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer,28424965
Pazopanib for the treatment of renal cancer,21470066
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism,20389299
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma,26308596
Bisphosphonates: mechanism of action and role in clinical practice,18775204
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis,23404816
Zoledronic acid in breast cancer: latest findings and interpretations,22084643
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results,23047045
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin- releasing hormone agonist–induced bone loss in men with prostate cancer,17369566
Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients,24120382
Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma,23642545
Recommendations for zoledronic acid treatment of patients with bone metastases,15632252
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early- stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial,21641868
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial,25035292
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates,18558816
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus,25414052
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial,25035292
Pharmacological attempts to improve the bioavailability of oral etoposide,7497581
Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide,11857004
Safe administration of oral etoposide after hypersensitivity reaction to intravenous etoposide,7858295
Effect of grapefruit juice intake on etoposide bioavailability,12389073
Leaching of diethylhexyl phthalate from multilayer tubing into etoposide infusion solutions,15700892
Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous etoposide solution,11975699
Stability of etoposide solution for oral use,1471649
The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide,2994705
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial,15738537
Ipilimumab: a novel treatment for metastatic melanoma,21505108
Improved survival with ipilimumab in patients with metastatic melanoma,20525992
Pulmonary sarcoid-like granulomatosis induced by ipilimumab,22547608
Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities,22253555
Ipilimumab in the treatment of metastatic melanoma: management of adverse events,24570590
A Canadian perspective on the subcutaneous administration of rituximab in non- Hodgkin lymphoma,28270723
Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting,17244675
Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma,19582454
Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous b-cell lymphoma,10724200
Intralesional rituximab for cutaneous B-cell lymphoma,11422050
Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma,15787825
Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response,17903214
Intrapleural instillation of rituximab for the treatment of malignant pleural effusions in NHL,15533844
Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the cns and resistant to conventional therapy,19036096
Intraventricular treatment of relapsed central nervous system lymphoma with the anti- CD20 antibody rituximab,15194546
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome,20709661
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program,9704735
Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation,20950702
High-dose methotrexate and rituximab with dererred radiotherapy for newly diagnosed primary B-cell CNS ymphoma,20511181
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom lymphoma group LY06 study,12181251
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen,8622041
Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity,15160953
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia,15955905
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma,11807147
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis,17470738
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone,11564066
Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia,11709569
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial,16873669
Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis,18500519
Profile of olaparib in the treatment of advanced ovarian cancer,27186080
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation,25366685
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer,22452356
PARP inhibitors in ovarian cancer: clinical evidence for informed treatment decisions,26669450
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies,23045577
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib,25360238
2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology,12065567
Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate,6088020
Inability of medroxyprogesterone acetate to down regulate estrogen receptor level in human breast cancer,2137722
Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells,2970295
Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the gynecologic oncology group,10561210
Increased survival with enzalutamide in prostate cancer after chemotherapy,22894553
Hand-foot and stump syndrome to sorafenib,17235051
Keratoacanthomas associated with sorafenib therapy,17190642
Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma,17396743
Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006,17008686
Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib,17116852
Effect of arsenic trioxide on QT interval in patients with advanced malignancies,14512391
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia,11559723
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet,18812465
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia,16373661
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide,9801394
Degarelix: a review of its use in patients with prostate cancer,24756432
Milk could decrease the bioavailability of 6-mercaptopurine,2618973
Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia,3153245
The effect of food on the oral administration of 6-mercaptopurine,3757164
Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia,2615529
Oral mercaptopurine in childhood leukemia: influence of food intake on bioavailability,2702064
Thiopurine S-methyltransferase as a target for drug interactions,15952020
The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients,16181300
Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia,6607783
Reduction in bioavailability of 6-mercaptopurine on simultaneous administration with cow's milk,16849279
Interaction between mercaptopurine and milk,18045784
Goats' milk xanthine oxidoreductase is grossly deficient in molybdenum,15068060
Purification and partial characterisation of camel milk xanthine oxidoreductase,16026028
Physicochemical and kinetic properties of purified sheep's milk xanthine oxidoreductase,15453470
Purification and partial characterization of xanthine oxidase from human milk,1627588
Administration of liquid dose forms of 6-mercaptopurine,7748699
Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly,18824557
Effects of some clinically encountered drugs on steroid synthesis and degradation,6247603
Fatal hepatitis following irradiation and vincristine,7148508
Ischemic heart disease associated with vincristine and doxorubicin chemotherapy,11724093
Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy,2373666
Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports,9855331
Vincristine-itraconazole interaction: cause for increasing concern,12368705
Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature,11764105
Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies,11697438
Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia,11255732
Combined therapy for carcinoma of the nasopharynx: a report of 49 cases,8509695
Intra-arterial chemotherapy of head and neck tumours,95463
Hepatic intra-arterial infusion of vincristine,6467495
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development,26589495
Review of a promising new agent - pemetrexed disodium,12673697
Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors,11524555
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma,12860938
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin,10506594
Clodronate: a review of its use in breast cancer,10495073
Timing of food intake has a marked effect on the bioavailability of clodronate,10913925
Acute management of cancer-related hypercalcemia,8740333
Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity,9358945
Tolerability and safety of clodronate therapy in bone diseases,1831808
Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma,17598839
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates,18558816
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus,25414052
Symptomatic hypocalcemia with oral clodronate,9494315
Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside,1825614
Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer,8884875
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer,8418243
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia,11287972
Pharmacokinetics and Pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients,14990650
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias,12200353
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor,11287975
First case of immune-mediated haemolytic anaemia associated to imatinib mesylate,14703696
Severe hemolytic anemia and skin reaction in a patient treated with imatinib,12796039
Adverse events after imatinib mesylate therapy,11873781
Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case,12970792
Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones,12646955
Adverse events after imatinib mesylate therapy,11873781
Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia,12353320
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate,16862153
Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia,12835733
Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia,12431246
Lichenoid eruption to STI 571,12111794
Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation,12707720
Imatinib mesylate causes hypopigmentation in the skin,15160360
Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate,12648085
Imatinib mesylate and gray hair,12167692
Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia,14574325
Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib,14511021
Gynaecomastia in men with chronic myeloid leukaemia after imatinib,12801741
Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis,12357373
Fatal hepatic necrosis following imatinib mesylate therapy,14568907
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate,12631595
Hypersensitivity pneumonitis related to imatinib mesylate,12377975
Unexpected pleural effusions in 3 pediatric patients treated with STI-571,12439048
Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia,12916879
Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia,11773197
Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase,12419759
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate,12604417
Practical management of patients with chronic myeloid leukemia receiving imatinib,12668652
Intramuscular edema as a complication of treatment with imatinib,12682642
Cerebral oedema as a possible complication of treatment with imatinib,12049868
Managing cutaneous reactions to imatinib therapy,12412577
Imatinib induces hypothyroidism in patients receiving levothyroxine,16198662
Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function,12394270
Imatinib administration in two patients with liver metastases from GIST and severe jaundice,14562006
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs,12074691
Idarubicin: a brief overview on pharmacology and clinical use,9147715
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity,15169927
Toxicity of the topoisomerase II inhibitors,15794715
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects,17577017
American society of clinical oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants,19018081
Effectiveness of long-term cabergoline treatment for giant prolactinoma: Study of 12 men,17287412
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points,8656243
Intravesical idarubicin: a dose-finding study,8603442
Pharmacokinetics of Anticancer Drugs in Children,3555940
Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin,15685452
Treatment of cyclophosphamide-induced hemorrhagic cystitis with prostaglandins,8068996
Side effects of adjuvant treatment of breast cancer,11430330
Clinical Significance of Cyclophosphamide-induced Cardiotoxicity,15750266
Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia,1346293
Prevention and treatment of hemorrhagic cystitis,9250547
Pulmonary fibrosis induced by cyclophosphamide,11485142
Oropharyngeal sensation associated with rapid intravenous administration of cyclophosphamide (NSC-26271),4660633
Amiodarone and cyclophosphamide: potential for enhanced lung toxicity,11438830
Stability of cyclophosphamide in extemporaneous oral suspensions,20103616
Drug Prescribing in Renal Failure,378644
Total body irradiation and cyclophosphamide in a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis,9758350
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency,11918757
Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin,10458260
Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer,10768867
Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study,7547255
Dose optimisation of carboplatin in adults,7825958
Clinical pharmacokinetics and dose optimisation of carboplatin,9314610
Pharmacokinetics of carboplatin after intraperitoneal administration,1859253
Clinical pharmacokinetics of carboplatin in children,8137457
Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma,10398179
Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions,8531847
Hypersensitivity to carboplatin in children,10064185
Clinical features of hypersensitivity reactions to carboplatin,10561172
Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy,9296241
Application of the area under the curve of carboplatin in predicting toxicity and efficacy,10189407
Prediction of creatinine clearance from serum creatinine,1244564
Carboplatin pharmacokinetics in young children with brain tumors,8765431
Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer,10231137
Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency,8139735
Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study,1403039
The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review,7825959
Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide,11857004
Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity,18337441
Hypersensitivity reactions to etoposide phosphate,23740378
Antiandrogens in the treatment of prostate cancer,17007995
Lack of effect of sex and disease state on the pharmacokinetics of porfimer sodium,16928153
Urticaria and respiratory distress due to porfimer sodium,11054995
Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer,24435321
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations,23816960
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells,16397052
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study,18711175
Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines,16451401
Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient [1],15772697
Skin lesions induced by bortezomib,16464759
Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: case report,16038531
Bortezomib-induced severe hepatitis in multiple myeloma: a case report,15738379
Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma,16410442
Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia,16305302
Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration,15449188
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma,18768528
A practical update on the use of bortezomib in the management of multiple myeloma,16401713
Antioxidants block proteasome inhibitor function in endometrial carcinoma cells,18176107
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors,19190249
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study,17138816
A pharmacokinetically based phase I-II study of single-dose actinomycin D (NSC- 3053),1260785
Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2,21222245
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia,20194866
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study,24421329
Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin,28776425
Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia,29517084
Improved survival with vemurafenib in melanoma with BRAF V600E mutation,21639808
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib,22356324
Progression of RAS-mutant leukemia during RAF inhibitor treatment,23134356
Current management and novel agents for malignant melanoma,22333219
Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network,26985376
Vemurafenib significantly decreases glomerular filtration rate,24267914
Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib,26182194
Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma,22742884
Cardiovascular toxicity with cancer chemotherapy,9442980
Proposal for classifying the acute emetogenicity of cancer chemotherapy,8996130
Toxicity of the topoisomerase II inhibitors,15794715
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects,17577017
American society of clinical oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants,19018081
Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d’Oncologie Pédiatrique,12637473
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points,8656243
Treatment of chemotherapy extravasation: current status,6378380
Vesicant extravasation: myths and realities,7708525
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma,19826128
Romidepsin for the treatment of T-cell lymphomas,23784158
Denosumab in the prevention of skeletal-related events in patients with bone metastases from solid tumours,21668042
Osteonecrosis of the jaw in a patient on denosumab,20149510
American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer,21343561
Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone,17237842
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer,16983113
Risk of fracture after androgen deprivation for prostate cancer,16093991
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer,16258089
Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer,16566812
Strategies to prevent chemotherapy-induced bone loss in women with breast cancer,15807926
Therapy Insight: osteoporosis during hormone therapy for prostate cancer,16474548
Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma,12548577
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada,12427685
Flare Associated with LHRH-Agonist Therapy,16986003
Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months,19071884
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures,7851006
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma,11418482
Thalidomide is distributed into human semen after oral dosing,11560881
Antitumor activity of thalidomide in refractory multiple myeloma,10564685
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients,11435324
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy,11739195
Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma,11325646
Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent,10871741
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma,10848786
Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug,10691870
Thalidomide and low-dose dexamethasone in myeloma treatment,11472379
Thalidomide in refractory and relapsing multiple myeloma,11740814
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation,11325648
Thalidomide in the treatment of graft-versus-host disease,2204450
Thalidomide treatment for chronic graft-versus-host disease,2043478
Successful treatment with thalidomide of acute graft-versus-host disease after bone- marrow transplantation,2891954
Thalidomide as salvage therapy for chronic graft-versus-host disease,7579470
The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children,9543061
The use of thalidomide in chronic refractory graft versus host disease,11476911
Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model,2939610
Thalidomide for treatment of graft-versus-host disease,3056547
Thalidomide for the treatment of chronic graft-versus-host disease,1549151
Response to thalidomide therapy in refractory chronic graft-versus-host disease,11081386
Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation,7711671
Thalidomide for graft-versus-host disease after bone marrow transplantation,2893167
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial,12039921
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes,11493439
Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody,11307775
Deep venous thrombosis and thalidomide therapy for multiple myeloma,11419443
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy,11520815
Thalidomide and thrombosis in patients with multiple myeloma,11602422
Thromboembolic events during treatment with thalidomide,12043695
Severe cutaneous ulceration following treatment with thalidomide for GVHD,11281398
Thalidomide-associated gynecomasty in a patient with multiple myeloma,14502266
Hypothyroidism in patients with multiple myeloma following treatment with thalidomide,11904117
Thalidomide-associated hepatitis: a case report,11279644
Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma,11956286
Intractable insomnia after cessation of treatment with thalidomide,11339241
Transient secondary amenorrhea in women treated by thalidomide,11809598
Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study,15210898
Thalidomide induces amenorrhea in patients with lupus disease,9870886
A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients,7911813
Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview,11994029
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer,15014181
Radiation recall induced by tamoxifen,1351618
Radiation recall - Another call with tamoxifen,10606426
Radiation recall in a patient with breast cancer treated for tuberculosis,7621852
Tamoxifen and gallstone formation in postmenopausal breast cancer patients: retrospective cohort study,12658480
Recurrent vulvovaginal candidiasis associated with long-term tamoxifen treatment in postmenopausal women,8841260
Severe hypertriglyceridaemia and hypercholesterolaemia associated with tamoxifen use,9764383
Delayed severe hypertriglyceridemia from tamoxifen,9229698
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer,1542321
Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years,7979855
The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women,7503087
Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer,8571997
Ovarian cysts in women receiving tamoxifen for breast cancer,10206289
Hot flushes in breast cancer patients,16343926
Uterine sarcomas in breast cancer patients treated with tamoxifen,16681774
Tamoxifen and cataracts: a null association,15377843
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study,9747868
Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide,2393854
The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer,9888474
Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer,16361559
Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer,10499602
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer,10430063
A hot flash on tamoxifen metabolism,14652227
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment,16815318
Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin,9871429
Thyroid function in postmenopausal breast cancer patients treated with tamoxifen,9587161
Effect of adjuvant tamoxifen therapy on thyroid function in postmenopausal women with breast cancer,9885376
Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition,15286089
Effect of impaired renal function on tamoxifen,6094920
Tamoxifen in liver disease: Potential exacerbation of hepatic dysfunction,9834826
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression,18829880
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine,14652237
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study,20142325
Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program,16197986
Regioselective metabolism of taxoids by human cyp3A4 and 2C8: structure-activity relationship,11901098
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study,17935602
A review of clinical experience with paclitaxel extravasations,12690542
Prophylaxis for paclitaxel hypersensitivity reactions,11573863
Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias,15118009
Myalgias and arthralgias associated with paclitaxel,12632867
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents,19354063
A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel,11855881
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens,14974481
Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer,12228205
Taxanes in elderly breast cancer patients,15145508
Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer,15068314
Intraperitoneal chemotherapy comes of age,16394306
Premedication strategy for weekly paclitaxel,12197222
Weekly paclitaxel in women age 65 and above with metastatic breast cancer,12083634
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer,11709565
Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions,9396407
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment,18204842
Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study,7902425
Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy,15892593
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma,11346336
Pharmacokinetics and pharmacodynamics of hydroxyurea,9592619
Hydroxyurea interferes negatively with triglyceride measurement by a glycerol oxidase method,4017240
Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone,17237842
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer,16983113
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer,16258089
Risk of fracture after androgen deprivation for prostate cancer,16093991
Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer,16566812
Strategies to prevent chemotherapy-induced bone loss in women with breast cancer,15807926
Therapy Insight: osteoporosis during hormone therapy for prostate cancer,16474548
Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma,12548577
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada,12427685
Flare Associated with LHRH-Agonist Therapy,16986003
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer,23724913
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer,20979469
Ruxolitinib for the treatment of myelofibrosis: its clinical potential,22399854
Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis,22034658
Adaptive control methods for the dose individualisation of anticancer agents,10803455
Drug interactions in cancer therapy,16794637
Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d’Oncologie Pédiatrique,12637473
Toxicity of the topoisomerase II inhibitors,15794715
Abiraterone and increased survival in metastatic prostate cancer,21864182
Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome,11368288
Guidelines for the administration of amifostine,8783665
Clinical status and optimal use of amifostine,10027198
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin- induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer,8683243
Protection by amifostine of cyclophosphamide-induced myelosuppression,10348259
Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects,10348264
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer,10506598
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study,11335791
Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide,11459207
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors,10958599
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation,11161394
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer,11139307
Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors,9815738
Amifostine for protection from antineoplastic drug toxicity,9099346
A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer,17141978
Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer,11704311
Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer,11849797
A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma,10725619
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer,11181692
Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer,11917277
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results,11917284
Alteration of radiation-induced hematotoxicity by amifostine,11704315
Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01,11917283
Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study,10829042
Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent),6312315
Influence of the administration of amifostine on the pharmacokinetics of 5- fluorouracil in patients with metastatic colorectal carcinoma,10667836
Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo,8976819
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice,9166935
Pharmacokinetics of amifostine and its metabolites in patients,9337685
Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients,9516919
No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients,12012141
Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer,12577250
A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury,12128116
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors,10757556
New therapeutic options in colon cancer: focus on oxaliplatin,11998605
Management of pharyngolaryngeal dysesthesia associated with oxaliplatin therapy,12929279
Oxaliplatin: practical guidelines for administration,15208819
Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice,17623621
Oxaliplatin: a review of its use in the management of metastatic colorectal cancer,10408744
Oxaliplatin clinical activity: a review,10936465
Oxaliplatin: a new therapeutic option in colorectal cancer,10606258
Clinical pharmacokinetics of oxaliplatin: a critical review,10778943
Pharmacokinetics and safety profile of oxaliplatin,9609104
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer,10623704
Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients,10592105
Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients,10355582
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma,10930799
Extravasation of Oxaliplatin (Eloxatin((R))) - Clinical Course,11441243
Vesicant characteristics of oxaliplatin following antecubital extravasation,12924452
A case report of oxaliplatin extravasation,12796037
Oxaliplatin-induced Torsades de pointes and long QT syndrome in a patient with gastric cancer,23368679
Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma,18618340
A case of oxaliplatin-related posterior reversible encephalopathy syndrome,17311705
Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin,19632931
Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin,18024878
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate,2348469
Second-line chemotherapy with weekly oxaliplatin and high-dose 5- fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study,10761750
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function,10663631
Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy,11405181
Liposomal anthracycline administration and toxicity management: a nursing perspective,15717743
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions,12954584
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia,24450857
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system,27268272
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer,18316791
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic,17159497
Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia,18251285
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer,17470858
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer,17671985
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities,18154212
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study,17466895
Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations,19229368
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies,16033478
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors,19203894
Oral fludarabine therapy in chronic lymphocytic leukemia - Increased convenience,15079151
Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia,15079149
Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia,16019557
Hepatitis B virus reactivation after fludarabine-based regimens for indolent non- Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations,14607759
Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia,12200396
Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-cd20 monoclonal antibody rituximab,16430461
Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia,16542723
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes,12374451
Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure,15876260
Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard),3783205
Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia,10468856
Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review,12487784
Successful treatment of essential thrombocythemia with anagrelide in a child,9589087
Treatment of children with anagrelide for thrombocythemia,9787322
The clinical pharmacology of topoisomerase I inhibitors,9779877
Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma,10549508
Topotecan: a new topoisomerase I inhibiting antineoplastic agent,9876816
An overview of the clinical pharmacology of topotecan,9122737
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks,7805183
Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience,9885371
Phase II study of oral topotecan in advanced non-small cell lung cancer,10741709
Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma,9533548
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function,8637048
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study,9626225
Topotecan: a review of its efficacy in small cell lung cancer,10493279
New developments in the treatment of acute myeloid leukemia: focus on topotecan,10622225
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia,9922042
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia,10561358
Topotecan in the treatment of non-small cell lung cancer,9425959
Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study,9469346
Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study,9703003
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors,10986062
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy,7884429
Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis,15634030
Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA,12107550
Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases,2131034
Bladder cancer: current optimal intravesical treatment,16294610
Comprehensive pharmacology and clinical efficacy of aromatase inhibitors,10473018
Use of aromatase inhibitors in breast carcinoma,10732791
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer,8417819
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment,10885600
Absolute bioavailability of letrozole in healthy postmenopausal women,9429742
A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma,9217033
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,14551341
Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer,10499602
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer,10430063
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies,10576660
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies,10561328
Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer,9815639
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high- grade glioma,9332462
Phase I trial of temozolomide using an extended continuous oral schedule,9766665
Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide,10501912
Temozolomide stability in extemporaneously compounded oral suspensions,23974320
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,15758009
